Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS4: molecularly selected therapy in colorectal cancer
ISRCTN90061546Phase 2Completed
- Sponsor
- Medical Research Council
- Start
- Dec 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of sapitinib and capecitabine in colorectal cancer (CRC) (4 arms), sponsored by Medical Research Council. Primary endpoint: Progression-free survival. Started Dec 2013; status: completed.
02
Drugs
sapitinibcapecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ISRCTN90061546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN90061546.